{"id":"NCT02745080","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis","officialTitle":"A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-03","primaryCompletion":"2019-12-30","completion":"2019-12-30","firstPosted":"2016-04-20","resultsPosted":"2021-01-27","lastUpdate":"2021-01-27"},"enrollment":853,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":["AIN457"]},{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":[]}],"arms":[{"label":"Secukinumab 300 mg s.c.","type":"EXPERIMENTAL"},{"label":"Adalimumab 40 mg s.c.","type":"ACTIVE_COMPARATOR"}],"summary":"This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are na√Øve to biologic therapy and are intolerant or having inadequate response to conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs).","primaryOutcome":{"measure":"Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52","timeFrame":"Week 52","effectByArm":[{"arm":"Secukinumab 300 mg s.c.","deltaMin":67.4,"sd":null},{"arm":"Adalimumab 40 mg s.c.","deltaMin":61.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0719"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":156,"countries":["United States","Australia","Bulgaria","Canada","Czechia","Denmark","Estonia","Finland","France","Germany","Greece","Hungary","Iceland","India","Israel","Italy","Latvia","Lithuania","Netherlands","Poland","Portugal","Russia","Slovakia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["37097894","32386593"],"seeAlso":["https://pubmed.ncbi.nlm.nih.gov/32386593/"]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":426},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Psoriatic arthropathy","Diarrhoea","Headache"]}}